LinkedIn
icn_podcast Podcasts
View All Upcoming Courses
Specialty
Course Type
Search
Login
Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Neuro-Ophthalmology Oculoplastics Optometry Retina Women's Health View All Courses
Course Type
Evaluation Supplement Multimedia Webinar Podcast In-Person Multi-part Collection
Search
Login
Menu

DED Outlook: Understanding the Disease and Treatments on the Horizon

By: Damon Dierker, OD, FAAO; Patrick M. Vollmer, OD, FAAO

Begin Course

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 1

As new and novel approaches to the treatment of dry eye come to fruition, it is important for eye care providers to stay up to date regarding the options available for rapid symptom relief and for individualizing treatment regimens for their patients. This educational webinar will focus on those topics and more, including data on the significance of the trigeminal nerve in ocular surface disorders.

Expiration Date: Friday, May 5, 2023
Release Date: May 11, 2021

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Summarize the mechanism of action of dry eye disease (DED)
  • Describe the significance of the trigeminal nerve in ocular surface disorders
  • Evaluate the impact that chronic diseases, certain medications, and ocular surgery can have on the health of the ocular surface
  • Compare the current and potential future treatments for DED

Accreditation and Designation Statement

Sponsored by:

This activity, COPE Activity Number 121780, is accredited by COPE for continuing education for optometrists. 
This course is approved for 1.0 hours CE. 
Course #: 72664-AS
Activity #: 121780

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures

Damon Dierker, OD, FAAO

Director, Optometric Services
Eye Surgeons of Indiana
Indianapolis, IN

Patrick M. Vollmer, OD, FAAO

Director of Clinic & Research Divisions
Vita Eye Clinic
Shelby, NC

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Damon Dierker, OD, FAAO, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Bio-Tissue, Carl Zeiss Meditec, Eyevance, Glaukos, Johnson & Johnson, Kala, Lumenis, MacuLogic, Notal Vision, Novartis, Sight Sciences, and Sun Pharma. Grant/Research Support: Allergan, Ocular Therapeutix, and Tarsus. Speaker’s Bureau: Alcon, Allergan, Bio-Tissue, Glaukos, Lumenis, MacuLogic, MacuHealth, Notal Vision, Novartis, Osmotica, Scope, and TearLab.

Patrick M. Vollmer, OD, FAAO, has had no financial agreement or affiliation with a commercial interest during the past year.

The Evolve staff and planners have no financial relationships with commercial interests. 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve, or Oyster Point Pharma.

Begin Course